Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 117Cyclophosphamide 109pembrolizumab 88Radiotherapy 83Nivolumab 73Cisplatin 68fludarabine 65Biopsy 60Carboplatin 59Standard of Care 49Radiosurgery 45Gemcitabine 44Paclitaxel 42Dexamethasone 42Radiation 39Doxorubicin 39Rituximab 38Blood Specimen Collection 37Bevacizumab 37venetoclax 36Cytarabine 36Surveys and Questionnaires 35fludarabine phosphate 33Capecitabine 33Temozolomide 31Radiotherapy, Intensity-Modulated 31Practice Guidelines as Topic 31Ipilimumab 28Interviews as Topic 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pegloticase × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡